ADARx Pharmaceuticals Announces Clinical Data Presentation at the American Society of Nephrology (ASN) Kidney Week 2025
SAN DIEGO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present initial Phase 1 clinical data for ADX-038, an investigational small interfering RNA (siRNA) therapeutic candidate being evaluated for the treatment of complement factor mediated diseases. The poster presentation will be given at the ASN’s Kidney Week meeting being held November 6-9, 2025, in Houston, Texas.
Title: Interim Phase 1 Study Results of ADX-038: A Novel siRNA Against Complement Factor B, and Next Steps in IgAN and C3 Glomerulopathy (C3G)
Poster Number: FR-PO0832
Date/Time: Friday, November 7 from 10:00 a.m. to 12:00 p.m. CST
About ADX-038
ADX-038 is an investigational siRNA therapy designed to selectively cleave complement factor B (CFB), a validated target in the complement pathway. The complement system is a key component of the immune system that enhances, or complements, the activity of both adaptive and innate immune responses. Dysregulation of this system has been implicated in a broad range of autoimmune and inflammatory diseases. As such, ADX-038 offers the potential to serve as a pipeline-in-a-product, addressing multiple indications through a single therapeutic approach. Multiple Phase 2 clinical trials have been initiated to evaluate the safety and efficacy of ADX-038 in patients with complement-mediated diseases including renal diseases (immunoglobulin A nephropathy (IgAN) and complement 3 glomerulopathy (C3G)), geographic atrophy (GA) secondary to age-related macular degeneration (AMD), and paroxysmal nocturnal hemoglobinuria (PNH).
About ADARx Pharmaceuticals
ADARx Pharmaceuticals, Inc. is a late-stage clinical biotechnology company dedicated to transforming cutting-edge science into next-generation RNA medicines across a broad range of therapeutic areas. We have developed proprietary technology to control the expression of specific disease drivers with highly selective RNA targeted therapies with the goal of delivering life-changing treatments for patients with urgent unmet medical needs. ADARx is focused on advancing and expanding a deep pipeline of highly potent, durable and selective RNA-targeted therapeutic candidates, developing product candidates for the treatment of complement-mediated, genetic, cardiovascular, thrombotic, central nervous system and metabolic (obesity) diseases. In addition to our wholly-owned programs, we have entered into a collaboration and license option agreement with AbbVie to develop siRNA therapeutics across multiple disease areas, including neuroscience, immunology and oncology. Follow ADARx on LinkedIn.
Contacts Investors: ir@adarx.com Media: teri@redhousecomms.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
